Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast CancerSuparna Wedam, Sandra M. Swain|Journal of Clinical Oncology|2006Cited by 523
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer Gao, Tatiana M. Prowell, Amna Ibrahim et al.|The Lancet Oncology|2019Cited by 299
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast CancerLaleh Amiri‐Kordestani, Patricia Cortazar, Lijun Zhang et al.|Clinical Cancer Research|2014Cited by 153
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast CancerSuparna Wedam, Julia A. Beaver, Lola A. Fashoyin‐Aje et al.|Clinical Cancer Research|2020Cited by 92
Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled AnalysisLynn Howie, Julia A. Beaver, Harpreet Singh et al.|Journal of Clinical Oncology|2019Cited by 91